MARKET

DNTH

DNTH

Dianthus Therapeutics Inc
NASDAQ
20.44
-0.15
-0.73%
Pre Market: 20.00 -0.44 -2.15% 04:13 03/21 EDT
OPEN
20.28
PREV CLOSE
20.59
HIGH
22.25
LOW
20.08
VOLUME
1
TURNOVER
0
52 WEEK HIGH
33.77
52 WEEK LOW
18.13
MARKET CAP
656.64M
P/E (TTM)
-8.0138
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DNTH last week (0310-0314)?
Weekly Report · 4d ago
Dianthus Therapeutics Price Target Maintained With a $36.00/Share by Wedbush
Dow Jones · 03/12 14:35
Wedbush Reiterates Outperform on Dianthus Therapeutics, Maintains $36 Price Target
Benzinga · 03/12 14:24
Dianthus Therapeutics Price Target Maintained With a $84.00/Share by Guggenheim
Dow Jones · 03/12 14:04
Guggenheim Reiterates Buy on Dianthus Therapeutics, Maintains $84 Price Target
Benzinga · 03/12 13:53
Dianthus Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones · 03/12 11:18
HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $40 Price Target
Benzinga · 03/12 11:08
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 03/11 21:10
More
About DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.

Webull offers Dianthus Therapeutics Inc stock information, including NASDAQ: DNTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DNTH stock methods without spending real money on the virtual paper trading platform.